2007
DOI: 10.2174/156802607782507402
|View full text |Cite
|
Sign up to set email alerts
|

Recent Advances in the Development of Amyloid Imaging Agents

Abstract: Excessive amyloid-beta (Abeta) deposition in the brain is one of the most crucial events in the early pathological stage of Alzheimer's disease (AD). Therefore, Abeta deposits have enough potential to become a useful biomarker for not only an early diagnosis of AD, but also for the assessment of the clinical efficacy of anti-Abeta therapies, if they can be measured non-invasively and reliably in living patients. As a potent candidate technique to measure this biomarker, PET amyloid imaging using a radioligand … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
46
0

Year Published

2009
2009
2023
2023

Publication Types

Select...
6
3

Relationship

2
7

Authors

Journals

citations
Cited by 73 publications
(46 citation statements)
references
References 149 publications
(232 reference statements)
0
46
0
Order By: Relevance
“…The optimization of pharmacokinetics is an important aspect in the development of a PET tracer (38). 18 F-THK-5105, 18 F-THK-5116, and 18 F-THK-5117 fulfilled the criteria of appropriate log P value (log P 5 1-3) for brain entry (39).…”
Section: Discussionmentioning
confidence: 99%
“…The optimization of pharmacokinetics is an important aspect in the development of a PET tracer (38). 18 F-THK-5105, 18 F-THK-5116, and 18 F-THK-5117 fulfilled the criteria of appropriate log P value (log P 5 1-3) for brain entry (39).…”
Section: Discussionmentioning
confidence: 99%
“…1,2 ThT's fluorescence emission is dramatically enhanced upon fibril binding, which makes ThT particularly useful in real-time detection of fibrils. ThT does not typically bind to monomeric proteins but appears to recognize and bind to some inherent structural features of amyloid fibrils.…”
mentioning
confidence: 99%
“…Several small molecular amyloid-binding agents have been designed for monitoring amyloid deposits in patients with MCI and AD and for evaluating the efficacy of antiamyloid therapy [8][9][10][11][12] . Furthermore, we have developed several benzoxazole derivatives as potential candidates for amyloid PET probes [13,14] .…”
mentioning
confidence: 99%